Hematologic Oncology

Investigators are exploring the novel genetic biomarker DGM1 as a potential predictor of benefit from the experimental agent enzastaurin in treatment-naïve patients with high-risk diffuse large B-cell lymphoma.

The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.

Novel combinations of biologic therapies, third-generation TKIs, and chemotherapy could lead to significantly higher cure rates for adult patients with acute lymphoblastic leukemia, with a number of early stage studies already showing promising results, according to Hagop M. Kantarjian, MD, at the 37th Annual CFS®.

Given that a watch-and-wait approach is a viable option, clinicians must carefully consider disease characteristics when selecting a treatment strategy in newly diagnosed follicular lymphoma.

With a variety of available agents in follicular lymphoma, determining which treatments to choose and how best to sequence them can be challenging.

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.

Gilteritinib demonstrated a higher remission rate and a statistically significant improvement in overall survival compared with salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia who harbor a FLT3 mutation.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Umbralisib (TGR-1202) met the primary endpoint of overall response rate in the follicular lymphoma cohort of the pivotal phase IIb UNITY-NHL trial, according to TG Therapeutics, Inc., the developer of the PI3K-delta inhibitor.

Treatment with iodine-131 apamistamab led to a high bone marrow transplant rate compared with salvage chemotherapy in elderly patients with relapsed/refractory acute myeloid leukemia.

The European Commission has approved gilteritinib as a single agent for the treatment of relapsed/refractory patients with FLT3-mutant acute myeloid leukemia.

Daria V. Babushok, MD, PhD, discusses treatment advances in paroxysmal nocturnal hemoglobinuria.

Alexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia.

Gary J. Schiller, MD, discusses the heterogeneity of acute myeloid leukemia.

Rituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.

The FDA has approved a supplemental Biologics License Application for romiplostim, updating its label to include data demonstrating sustained platelet responses in adults with immune thrombocytopenia. Romiplostim is approved for the treatment of adult patients with newly diagnosed or persistent who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.

Gary J. Schiller, MD, discusses the benefits and challenges of using venetoclax and glasdegib in patients with relapsed/refractory acute myeloid leukemia.

Jeff Sharman, MD, discusses the current approval and potential future roles for polatuzumab vedotin-piiq (Polivy) in diffuse large B-cell lymphoma.

Ruxolitinib met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease.

Daria V. Babushok, MD, PhD, provides insight into the latest developments in the treatment of patients with benign hematologic malignancies.

Noelle Frey, MD, MS, highlights various therapies available to patients with acute lymphocytic leukemia and the importance of measuring minimal residual disease.

In the phase II CLOVER-1 trial, investigators are evaluating whether CLR 131 will be an effective option for patients with difficult-to-treat relapsed or refractory B-cell lymphomas.

Alexander Edward Perl, MD, MS, discusses advancements in acute myeloid leukemia treatment and future approaches in the field.

Sunita Nasta, MD, discusses exciting updates in follicular lymphoma, diffuse large B-cell lymphoma, and T-cell lymphoma and the impact they will have on the upfront and relapsed/refractory paradigms.

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in treating patients with myelofibrosis.

Faculty from the George Washington Cancer Center to shed light on some of the current and future research efforts being made at their institution.

Imad Tabbara, MD, discusses the role of minimal residual disease testing in multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia, as well as emerging regimens in all 3 malignancies that are changing standards of care.

John F. DiPersio, MD, PhD, discusses the current state of CAR T-cell therapy, dual affinity re-targeting, bi-specific T-cell engagers, and antibody-drug conjugates for acute myeloid leukemia treatment.